Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part II: Treating Acquired Resistance and Evaluating Next-generation Therapies

Estimated Time
0.25 hr

Release Date
Nov 29, 2022

Expiration Date
Mar 31, 2024

The evolution of the non-small cell lung cancer (NSCLC) treatment landscape and the discovery of predictive biomarkers that can be targeted by novel therapies or combinations is facilitating more individualized treatment. However, drug resistance plays a major role in therapeutic failure and clinicians must stay alert to the current and emerging treatment options to provide optimal care. Are you ready to test your skills amongst your colleagues? Join us for Part 2 of this question and answer based educational activity Treating Acquired Resistance and Evaluating Next-generation Therapies where our oncology experts will:
  • Discuss treatment selection for patients with acquired resistance to targeted therapy
  • Present the latest clinical evidence on new and emerging targeted therapies
  • Provide strategies to promote patient engagement in their care


Accreditation and Disclosure Information

This CE activity is intended for community-based oncology clinicians including physicians, advanced practice providers (APPs, ie, NPs and PAs), nurses, and pharmacists who provide care for individuals with NSCLC.

After completing this CE activity, the participant should be better able to:
  • Recommend appropriate treatment for patients who develop resistance
  • Assess emerging safety and efficacy data for next generation therapies
Joint Accreditation with Commendation logo
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.25 contact hours and 0.08 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 0.25 (0.025 CEU) contact hour of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-121-H01-P
Type of Activity: Knowledge 
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until March 31, 2024. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Sanofi.
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Sanjay Juneja ,MD                        
Hematology, Medical Oncology
Chief of Oncology Line
Baton Rouge General  Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Advisory Board/Consultant for Daiichi Sankyo and Guardant 360.
Speakers’ Bureau with AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc. and Tempus.
Stock Ownership with Phenomune and xCures.
Independent Contractor for xCures.
Lauren Ritterhouse, MD, PhD
Associate Director, Center for Integrated Diagnostics
Assistant Professor, Harvard Medical School
Assistant Pathologist, Massachusetts General Hospital
Boston, MA
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Amgen, AstraZeneca, EMD Serono, Merck, Sanofi Genzyme
Narjust Florez, MD
Associate Director of The Cancer Care Equity Program
Thoracic Oncologist – Lowe Center For Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Boston, MA
Advisory Board/Consultant:  AstraZeneca, Bristol Myers Squibb/Novartis, Daiichi Sankyo, NeoGenomics, Pfizer
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Merck, Mirati
All of the relevant financial relationships of individuals for this activity have been mitigated.
The planners and content/peer reviewers from Medical Learning Institute, Inc., do not have any relevant financial relationship(s) to disclose with ineligible companies.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website:
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.